National Resilience, a U.S.-based biomanufacturing company, has recently announced the closure of several facilities and organizational restructuring. Given that Resilience is a major shareholder of Taiwan Bio-Manufacturing Corporation (TBMC), the news has sparked concerns about potential impacts on TBMC’s operations. On June 12, TBMC issued a formal statement clarifying that the two entities are completely independent in their operations and that TBMC's business activities remain unaffected by Resilience's restructuring.
According to the statement, while Resilience is one of TBMC’s shareholders, the two companies operate under entirely separate corporate structures with no direct or subordinate relationship in terms of business decision-making or operational management. TBMC reaffirmed its continued role as a reliable CDMO partner to global pharmaceutical clients in the Asia-Pacific region.
TBMC reported that its overall operations remain stable, with business development progressing steadily. In 2024, the company completed the establishment of its process and analytical laboratories, offering services to domestic and international clients in nucleic acid, cell and gene therapy, and biologics. Meanwhile, construction of its new facility in the Hsinchu Biomedical Science Park is proceeding on schedule. The QC laboratory is expected to be operational in Q3 this year, with the GMP manufacturing facility set for completion by year-end and commercial operations to begin in Q1 2025.
On the technical front, TBMC has successfully internalized its core technologies and trade secrets, supported by a professional and well-rounded operations team. While some technologies originated from Resilience through tech transfer, TBMC also utilizes proprietary technologies developed by the Industrial Technology Research Institute and the Development Center for Biotechnology. The technology transfer and training from Resilience were completed in early 2024, including key quality systems, GMP documentation, and design and engineering plans for GMP operations. Existing collaborations between the two companies will proceed as planned and remain unaffected.
Looking ahead, TBMC will continue collaborating with domestic academic and research institutions to license local innovations for application in emerging biopharmaceutical manufacturing processes, aiming to strengthen its technical independence and localization capabilities.
TBMC acknowledged that Resilience’s current restructuring involves resource reallocation across multiple sites, including filing Chapter 11 bankruptcy protection for certain subsidiaries in order to shut down six underutilized facilities. The company plans to consolidate resources at its core sites in Cincinnati, North Carolina, and Canada. TBMC emphasized that this is a strategic and financial restructuring process, not a full-scale bankruptcy, and that Resilience’s parent company operations remain unaffected. Resilience continues to receive support from capital markets and has recently secured $250 million in new funding to focus on commercial-scale manufacturing.
TBMC concluded by affirming its ongoing positive relationship and communication with Resilience and anticipates continued collaboration in market development and supply chain partnerships. However, in accordance with corporate governance principles, TBMC stated that it is neither able nor appropriate to comment on Resilience’s operational strategies or organizational adjustments.
Resource: 美國韌力傳關閉廠房及組織調整 TBMC聲明強調不受影響
